Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Conjugation of small interfering RNA (siRNA) to tris N-acetylgalactosamine [(GalNAc)3] can enable highly selective, potent, and durable knockdown of targeted proteins in the liver. However, potential knowledge gaps between in vitro experiments, preclinical species, and clinical scenarios remain. A minimal physiologically based pharmacokinetic-pharmacodynamic model for GalNAc-conjugated siRNA (GalNAc-siRNA) was developed using published data for fitusiran (ALN-AT3), an investigational compound targeting liver antithrombin (AT), to delineate putative determinants governing the whole-body–to-cellular pharmacokinetic (PK) and pharmacodynamic (PD) properties of GalNAc-siRNA and facilitate preclinical-to-clinical translation. The model mathematically linked relevant mechanisms: 1) hepatic biodistribution, 2) tris-GalNAc binding to asialoglycoprotein receptors (ASGPRs) on hepatocytes, 3) ASGPR endocytosis and recycling, 4) endosomal transport and escape of siRNA, 5) cytoplasmic RNA-induced silencing complex (RISC) loading, 6) degradation of target mRNA by bound RISC, and 7) knockdown of protein. Physiologic values for 36 out of 48 model parameters were obtained from the literature. Kinetic parameters governing (GalNAc)3-ASGPR binding and internalization were derived from published studies of uptake in hepatocytes. The proposed model well characterized reported pharmacokinetics, RISC dynamics, and knockdown of AT mRNA and protein by ALN-AT3 in mice. The model bridged multiple PK-PD data sets in preclinical species (mice, rat, monkey) and successfully captured reported plasma pharmacokinetics and AT knockdown in a phase I ascending-dose study. Estimates of in vivo potency were similar (∼2-fold) across species. Subcutaneous absorption and serum AT degradation rate constants scaled across species by body weight with allometric exponents of −0.29 and −0.22. The proposed mechanistic modeling framework characterizes the unique PK-PD properties of GalNAc-siRNA. SIGNIFICANCE STATEMENT Tris N-acetylgalactosamine (GalNAc)3–conjugated small interfering RNA (siRNA) therapeutics enable liver-targeted gene therapy and precision medicine. Using a translational and systems-based minimal physiologically based pharmacokinetic-pharmacodynamic (mPBPK-PD) modeling approach, putative determinants influencing GalNAc-conjugated siRNA (GalNAc-siRNA) functionality in three preclinical species and humans were investigated. The developed model successfully integrated and characterized relevant published in vitro–derived biomeasures, mechanistic PK-PD profiles in animals, and observed clinical PK-PD responses for an investigational GalNAc-siRNA (fitusiran). This modeling effort delineates the disposition and liver-targeted pharmacodynamics of GalNAc-siRNA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A methodology for performing global uncertainty and sensitivity analysis in systems biology
Marino, S., Hogue, I. B., Ray, C. J., & Kirschner, D. E. (2008) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2008.04.011 · Cited by 2,999 · cited 11×
“Introduction: 701 Discussion: 1824 (limit exceeded to address reviewers’ comments) List of non-standard abbreviations: ASGPR, asialoglycoprotein receptor; AT, antithrombin; FIH, firstin-human; GalNAc, N-acetylgalactosamine; GSA, global sensitivity analysis; KP, tissue:plasma partition coefficient; mPBPK, minimal physi…”
BackgroundInfluentialDelivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800 · cited 3×
“To derive the association rate constant (kon) for (GalNAc)3 with ASGPR (Table 2), a reported value of 2.48 nM for the equilibrium dissociation constant (KD) of this interaction was utilized (Kanasty et al., 2013).”
BackgroundMethodInfluentialGilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
Therapeutic siRNA: state of the art
Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586 · cited 4×
“…siRNA compounds, the clinical pipeline for GalNAc-siRNA therapy has increased substantially, with over a dozen late-stage trials to treat diverse liver-related diseases now underway (Khvorova and Watts, 2017; Springer and Dowdy, 2018; Setten et al., 2019; Debacker et al., 2020; Hu et al., 2020).”
BackgroundInfluentialThe current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443 · cited 2×
“…siRNA compounds, the clinical pipeline for GalNAc-siRNA therapy has increased substantially, with over a dozen late-stage trials to treat diverse liver-related diseases now underway (Khvorova and Watts, 2017; Springer and Dowdy, 2018; Setten et al., 2019; Debacker et al., 2020; Hu et al., 2020).”
BackgroundThe chemical evolution of oligonucleotide therapies of clinical utility
Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216 · cited 2×
“…siRNA compounds, the clinical pipeline for GalNAc-siRNA therapy has increased substantially, with over a dozen late-stage trials to treat diverse liver-related diseases now underway (Khvorova and Watts, 2017; Springer and Dowdy, 2018; Setten et al., 2019; Debacker et al., 2020; Hu et al., 2020).”
BackgroundNair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141 · cited 1×
“…to one strand of the siRNA duplex to lower immunogenicity, lipid nanoparticle formulations, and the development of tris N-acetylgalactosamine (GalNAc)3-conjugated siRNA (GalNAc-siRNA hereafter) (Layzer et al., 2004; Nair et al., 2014; Khvorova and Watts, 2017; Springer and Dowdy, 2018).”
BackgroundOvercoming cellular barriers for RNA therapeutics
Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139 · cited 5×
“These compounds offer the ability to target previously undruggable human and viral genomes to selectively knock down diseasecausing proteins (Dowdy, 2017).”
BackgroundInfluentialGalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics
Springer, A. D., & Dowdy, S. F. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0736 · Cited by 711 · cited 3×
“…siRNA compounds, the clinical pipeline for GalNAc-siRNA therapy has increased substantially, with over a dozen late-stage trials to treat diverse liver-related diseases now underway (Khvorova and Watts, 2017; Springer and Dowdy, 2018; Setten et al., 2019; Debacker et al., 2020; Hu et al., 2020).”
BackgroundHepatocytes: a key cell type for innate immunity
Zhou, Z., Xu, M.-J., & Gao, B. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.97 · Cited by 472 · cited 1×
“Upon binding to ASGPR, GalNAc-siRNA was assumed to distribute within the total volume of hepatocytes, which comprise 80% of the cellular volume of liver (Zhou et al., 2016).”
Background
Cited by
Lin, W., Chen, Y., Unadkat, J. D., Zhang, X., Wu, D., & Heimbach, T. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03274-2 · Cited by 137
GalNac-siRNA conjugate delivery technology promotes the treatment of typical chronic liver diseases
Qin, Z.-X., Zuo, L., Zeng, Z., Ma, R., Xie, W., Zhu, X., & Zhou, X. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2466767 · Cited by 32
“The GalNAc-siRNA delivery system involves conjugating a GalNAc ligand to the siRNA molecule, promoting its uptake and increasing the concentration within target cells, thus achieving the therapeutic goal [30] (Figure 1(A)).”
Li, B., Chen, Y., Zhang, Y., Qian, M., Shan, Q., Qian, J., & Guo, J. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2468855 · Cited by 6
“Anti-RNA treatments, such as antisense oligonucleotides and small interfering RNAs (siRNAs) that are linked with N-acetylgalactosamine (GalNAc), specifically focus on the liver [8].”
Metadata
- Authors
- Ayyar, V. S., Song, D., Zheng, S., Carpenter, T., & Heald, D. L.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 379
- Issue
- 2
- Pages
- 134-146
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W3195372454
- Cited by
- 49
- References
- 12
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans. https://app.cochat.ai/papers/10.1124/jpet.121.000805
- The paper
- Ayyar, V. S., Song, D., Zheng, S., Carpenter, T., & Heald, D. L. (2021). Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.121.000805
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.